{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T14:48:01Z","timestamp":1794581281043,"version":"4.9.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"DMK and ZMI Pharma donated the intramuscular naloxone used in this study."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-59932-7","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T14:28:31Z","timestamp":1747664911000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["A comparison of intramuscular (Zimhi) and intranasal naloxone (Narcan) in reversal of fentanyl-induced apnea: a randomized, crossover, open-label trial"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8767-1824","authenticated-orcid":false,"given":"Maarten A.","family":"van Lemmen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0289-6432","authenticated-orcid":false,"given":"Monique","family":"van Velzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise Y.","family":"Sarton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3161-3945","authenticated-orcid":false,"given":"Albert","family":"Dahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke","family":"Niesters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1422-3830","authenticated-orcid":false,"given":"Rutger M.","family":"van der Schrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"key":"59932_CR1","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/cpt.2696","volume":"112","author":"J Mann","year":"2022","unstructured":"Mann, J. et al. Development of a translational model to assess the impact of opioid overdose and naloxone dosing on respiratory depression and cardiac arrest. Clin. Pharmacol. Ther. 112, 1020\u20131032 (2022).","journal-title":"Clin. Pharmacol. Ther."},{"key":"59932_CR2","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1097\/ALN.0000000000004622","volume":"139","author":"M van Lemmen","year":"2023","unstructured":"van Lemmen, M. et al. Opioid overdose: limitations in naloxone reversal of respiratory depression and prevention of cardiac arrest. Anesthesiology 139, 342\u2013353 (2023).","journal-title":"Anesthesiology"},{"key":"59932_CR3","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1080\/17512433.2022.2114898","volume":"15","author":"A Bedene","year":"2022","unstructured":"Bedene, A. et al. Opioid epidemic: lessons learned and updated recommendations for misuse involving prescription versus non-prescription opioids. Exp. Rev. Clin. Pharmacol. 15, 1081\u20131094 (2022).","journal-title":"Exp. Rev. Clin. Pharmacol."},{"key":"59932_CR4","doi-asserted-by":"publisher","first-page":"e2351839","DOI":"10.1001\/jamanetworkopen.2023.51839","volume":"7","author":"DG Strauss","year":"2024","unstructured":"Strauss, D. G. et al. Intranasal naloxone repeat dosing strategies and fentanyl overdose: a randomized clinical trial and simulation study. JAMA Netw. Open 7, e2351839 (2024).","journal-title":"JAMA Netw. Open"},{"key":"59932_CR5","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12954-023-00904-9","volume":"20","author":"KR Marks","year":"2023","unstructured":"Marks, K. R. et al. Bystander preference for naloxone products; a field experiment. Harm. Red. J. 20, 171 (2023).","journal-title":"Harm. Red. J."},{"key":"59932_CR6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.5694\/j.1326-5377.2005.tb06550.x","volume":"182","author":"A-M Kelly","year":"2005","unstructured":"Kelly, A.-M. et al. Randomised trial of intranasal versus intramuscular naloxone in prehospital treatment for suspected opioid overdose. Med. J. Aus. 182, 24\u201327 (2005).","journal-title":"Med. J. Aus."},{"key":"59932_CR7","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1111\/j.1360-0443.2009.02724.x","volume":"104","author":"D Kerr","year":"2009","unstructured":"Kerr, D. et al. Randomized controlled trial comparing the effectiveness and safety of intranasal and intramuscular naloxone for the treatment of suspected heroin overdose. Addiction 104, 2067\u20132074 (2009).","journal-title":"Addiction"},{"key":"59932_CR8","doi-asserted-by":"publisher","first-page":"e1914977","DOI":"10.1001\/jamanetworkopen.2019.14977","volume":"2","author":"P Dietze","year":"2019","unstructured":"Dietze, P. et al. Effect of intranasal vs intramuscular naloxone on opioid overdose: a randomized clinical trial. JAMA Netw. Open 2, e1914977 (2019).","journal-title":"JAMA Netw. Open"},{"key":"59932_CR9","volume":"4","author":"M Yousefifard","year":"2020","unstructured":"Yousefifard, M. et al. Intranasal versus intramuscular\/intravenous naloxone for pre-hospital opioid overdose: a systematic review and meta-analysis. Adv. J. Emerg. Med. 4, e27 (2020).","journal-title":"Adv. J. Emerg. Med."},{"key":"59932_CR10","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1111\/add.15806","volume":"117","author":"AK Skulberg","year":"2022","unstructured":"Skulberg, A. K. et al. Comparison of intranasal and intramuscular naloxone in opioid overdoses managed by ambulance staff: a double-dummy, randomised, controlled trial. Addiction 117, 1658\u20131667 (2022).","journal-title":"Addiction"},{"key":"59932_CR11","unstructured":"U.S. Food and Drug Administration. ZIMHI https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/212854s000lbl.pdf (2021)."},{"key":"59932_CR12","unstructured":"U.S. Food & Drug Administration. NDA 208411\/S-004 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/208411Orig1s004lbl.pdf (2020)."},{"key":"59932_CR13","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.tcm.2023.03.006","volume":"3","author":"A El Sherbini","year":"2024","unstructured":"El Sherbini, A. et al. Opioids-induced inhibition of HERG ion channels and sudden cardiac death, a systematic review of current literature. Trend. Cardiovasc. Med. 3, 279\u2013285 (2024).","journal-title":"Trend. Cardiovasc. Med."},{"key":"59932_CR14","unstructured":"CDC. U.S. Overdose Deaths Decrease in 2023, First Time Since 2018. https:\/\/www.cdc.gov\/nchs\/pressroom\/nchs_press_releases\/2024\/20240515.htm (2024)."},{"key":"59932_CR15","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.bjae.2023.12.007","volume":"24","author":"SC Jansen","year":"2024","unstructured":"Jansen, C. S. & Dahan, A. Opioid-induced respiratory depression. BJA Edu. 24, 100\u2013106 (2024).","journal-title":"BJA Edu."},{"key":"59932_CR16","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1097\/ALN.0000000000004871","volume":"140","author":"BL Millas","year":"2024","unstructured":"Millas, B. L. & Varon, A. J. Naloxone for opioid overdose: comment. Anesthesiology 140, 857 (2024).","journal-title":"Anesthesiology"},{"key":"59932_CR17","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1111\/bph.16199","volume":"180","author":"R Hill","year":"2023","unstructured":"Hill, R. et al. Assessment of the potential of novel and classical opioids to induce respiratory depression in mice. Br. J. Pharmacol. 180, 3160\u20133174 (2023).","journal-title":"Br. J. Pharmacol."},{"key":"59932_CR18","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1007\/s00228-021-03190-1","volume":"77","author":"I Tylleskar","year":"2021","unstructured":"Tylleskar, I. et al. The pharmacokinetic interaction between nasally administered naloxone and the opioid remifentanil in human volunteers. Eur. J. Clin. Pharmacol. 77, 1901\u20131908 (2021).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"59932_CR19","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s00228-018-2443-3","volume":"74","author":"AK Skulberg","year":"2018","unstructured":"Skulberg, A. K. et al. Pharmacokinetics and -dynamics of intramuscular and intranasal naloxone: an exploratory study in healthy volunteers. Eur. J. Clin. Pharmacol. 74, 873\u2013883 (2018).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"59932_CR20","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1161\/CIR.0000000000001161","volume":"148","author":"EJ Lavonas","year":"2023","unstructured":"Lavonas, E. J. et al. 2023 American Heart Association focused update on the management of patients with cardiac arrest or life-threatening toxicity due to poisoning: an update to the American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation 148, e149\u2013e184 (2023).","journal-title":"Circulation"},{"key":"59932_CR21","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1097\/00000542-199410000-00013","volume":"81","author":"MJLJ van den Elsen","year":"1994","unstructured":"van den Elsen, M. J. L. J. et al. Does subanesthetic isoflurane affect the ventilatory response to acute isocapnic hypoxia in healthy volunteers? Anesthesiology 81, 860\u2013867 (1994).","journal-title":"Anesthesiology"},{"key":"59932_CR22","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1097\/ALN.0000000000004872","volume":"140","author":"M van Lemmen","year":"2024","unstructured":"van Lemmen, M. et al. Naloxone for opioid overdose: reply. Anesthesiology 140, 857\u2013859 (2024).","journal-title":"Anesthesiology"},{"key":"59932_CR23","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1097\/ALN.0000000000003156","volume":"132","author":"P Haouzi","year":"2020","unstructured":"Haouzi, P. et al. Severe hypoxemia prevents spontaneous and naloxone-induced breathing recovery after fentanyl-overdose in awake and sedated rats. Anesthesiology 132, 1138\u20131150 (2020).","journal-title":"Anesthesiology"},{"key":"59932_CR24","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1067\/mem.2003.148","volume":"41","author":"P Wax","year":"2003","unstructured":"Wax, P. et al. Unexpected, \u201cgas\u201d casualties in Moscow: a medical toxicology perspective. Ann. Emerg. Med. 41, 700\u2013705 (2003).","journal-title":"Ann. Emerg. Med."},{"key":"59932_CR25","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/cpt.2098","volume":"109","author":"CP France","year":"2021","unstructured":"France, C. P. et al. Countermeasures for preventing and treating opioid overdose. Clin. Pharmacol. Ther. 109, 578\u2013590 (2021).","journal-title":"Clin. Pharmacol. Ther."},{"key":"59932_CR26","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1093\/bja\/aei145","volume":"96","author":"A Dahan","year":"2005","unstructured":"Dahan, A. et al. comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br. J. Anaesth. 96, 825\u2013834 (2005).","journal-title":"Br. J. Anaesth."},{"key":"59932_CR27","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.drugpo.2017.06.010","volume":"46","author":"D Ciccarone","year":"2017","unstructured":"Ciccarone, D. Fentanyl in the US heroin supply: a rapidly changing risk environment. Int. J. Drug. Policy. 46, 107\u2013111 (2017).","journal-title":"Int. J. Drug. Policy."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59932-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59932-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59932-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T14:28:33Z","timestamp":1747664913000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59932-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["59932"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-59932-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5519093\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]},"assertion":[{"value":"10 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.D. received sponsor\/consultancy\/speaker fees from Enalare Therapeutics, Inc. (USA), Zmi Pharma, Inc. (USA), Takeda Pharmaceuticals Inter. A.G. (Switzerland). and Trevena, Inc. (USA), and an award from the US Food & Drug Administration (USA). The other authors report no conflict of interest. The study was sponsored by departmental funds. Intramuscular naloxone (ZIMHI) was kindly donated by DMK Pharmaceuticals Co., San Diego, CA, USA, and Zmi Pharma Inc, Carlsbad, CA, USA. These donors had no role in the study design, data collection, data analysis or manuscript writing.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4659"}}